Sartorius introduces Cubis II modular laboratory balances for improved operational efficiency and unmatched flexibility

Sartorius, a leading international supplier for the biopharmaceutical industry today announced the launch of the Cubis II portfolio of balances for R&D and analytical laboratories. The balances offer best-in-class performance including high capacity, excellent readability and robust stability and accuracy for all sample types.
Configurable hardware and software are fully customisable to maximise operational efficiency and experimental outcomes.
The Cubis II portfolio offers modern user interfaces, pharmaceutical and GxP compliance including data handling, data integrity and connectivity, ergonomic sample handling, easy process integration and unlimited communication at the highest level of accuracy and precision.
The balances were designed for intuitive operation, which is further aided by intelligent diagnostic systems. This guarantees a higher degree of repeatability of workflows, while lowering the possibility of human error during the measurement steps. Standard operating procedures can be configured as an approved workflow.
“Building upon the success of our Cubis line of laboratory balances, the Cubis II portfolio delivers exceptional performance and unmatched flexibility to meet the diverse needs of users in regulated environments,” said Gerry Mackay, member of the executive board, Sartorius Lab Products and Services division. “The Cubis II integrates seamlessly into existing workflows, unlike universal balances that may require a lab’s standard operating procedures to be adapted to the functionality of the balance.”

Key features and benefits of the Cubis II portfolio include:

Customised modularity
A modular design and broad selection of capacity and readability options, draft shield types, weighing pans and displays enables 6,000 possible hardware configurations for optimised
workflows. The initial hardware configuration can be enhanced over time with additional accessories. New software applications will be available ensuring long-term flexibility and adaptation to the evolving needs of the laboratory.

Powerful, adaptable and future-proof software
QApp software is adaptable to specific user requirements. A unique on-board QApp Center allows direct download of protocols and creation of customised applications to meet the needs of individual labs and users. Customers opting for a QApp package will receive all updates and new applications for that package, ensuring a future-proof solution.

Seamless connectivity
Cubis II balances are easily integrated with laboratory software and LIMS systems, eliminating the need for separate software islands. LIMS/data collection software connectivity ensures data accuracy and readiness for regulatory agency submission.

Confident Compliance
Cubis II balances fulfil all requirements for use in fully compliant processes for regulated markets such as pharmaceutical and biotechnology and applied markets including
environmental, food and beverage, medical, chemical and automotive.
The Cubis II is the first balance to support all the requirements to achieve CFR part 11 and EU annex 11 compliance in a paperless manner, eliminating the possibility of process data or signature falsification. The balances ensure an authenticated electronic record from data acquisition to analysis. Control over user access levels and protocols, including the ability to pull logins directly from the user’s LIMS system, ensures traceability and limits potential errors.

About Sartorius
The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, the company earned sales revenue of some 1.6 billion euros. Currently, more than 8,100 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.